Nystrom J S, Dyce B, Wada J, Bateman J R, Haverback B
Arch Intern Med. 1977 Jul;137(7):875-9.
Carcinoembryonic antigen (CEA) has been demonstrated in tumors and body fluids, suggesting that effusion fluid (EF) CEA titer might separate benign and malignant EF. Plasma and EF CEA titers were determined on 141 patients with either benign (86) or malignant (55) EF. Although plasma CEA titers separated patients with either a benign or malignant EF 56% of the time, this separation was better accomplished (90% of the time) using EF CEA (P less than .0001). A malignant EF was associated with an EF CEA titer greater than or equal to ng/ ml or when, in the range 5.0 to 9.9 ng/ml, the EF CEA titer was greater than twice the plasma CEA. Paired plasma and EF CEA titers may aid in determining the benign or malignant origin of an EF.
癌胚抗原(CEA)已在肿瘤和体液中得到证实,这表明积液(EF)CEA滴度可能有助于鉴别良性和恶性积液。对141例有良性积液(86例)或恶性积液(55例)的患者测定了血浆和积液CEA滴度。尽管血浆CEA滴度在56%的时间里能够区分有良性或恶性积液的患者,但使用积液CEA能更好地实现这种区分(90%的时间)(P小于0.0001)。恶性积液与积液CEA滴度大于或等于ng/ml相关,或者当积液CEA滴度在5.0至9.9 ng/ml范围内且大于血浆CEA的两倍时也相关。配对的血浆和积液CEA滴度可能有助于确定积液的良性或恶性来源。